Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer.
Five years of adjuvant tamoxifen treatment has been the gold standard for women with early hormone-responsive breast cancer. Results from two large phase III, adjuvant studies have indicated that the third-generation aro-matase inhibitors (AIs) letrozole and anastrozole offer greater protection against recurrence than tamoxifen in upfront substitution strategies in the first 5 years. Similarly, changeover to an AI (exemestane or anastrozole) after 2-3 years of tamoxifen has been more efficient to prevent recurrence than 5 years of tamoxifen. Most early breast cancer recurrences occur 5 or more years after surgery. Letrozole has been shown to offer greater protection against recurrence than placebo in the 5 years after a standard course of tamoxifen. The optimal adjuvant use (duration and sequencing) of AIs requires further investigation. Safety implications of treatment with these AIs for 5 years or more are closely monitored. The anticipated effects of estrogen deprivation on bone health may be treatable with bisphosphonates. Effects on the cardiovascular system, and other estrogen-sensitive systems such as the central nervous system, are currently examined. The AIs letrozole, anastrozole, and ex-emestane have recently replaced tamoxifen as the recommended adjuvant endocrine therapy, on the basis of greater efficacy and better tolerability.
Mundhenke
Christoph
C
University of Kiel, OB/GYN and Breast Center, Kiel, Germany.
Schem
Christian
C
Jonat
Walter
W
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
9747868
N Engl J Med. 2004 Mar 11;350(11):1081-92
15014181
Lancet. 2005 Jan 1-7;365(9453):60-2
15639680
Obstet Gynecol Surv. 2004 Jun;59(6):446-55; quiz 485
15167766
J Bone Miner Res. 2002 Jan;17(1):172-8
11771665
Br J Cancer. 1999 Mar;79(7-8):1179-81
10098755
J Clin Oncol. 2007 Jul 1;25(19):2664-70
17563395
Lancet. 2007 Feb 17;369(9561):559-70
17307102
Semin Oncol. 2003 Dec;30(6):763-75
14663777
J Clin Oncol. 2006 Aug 1;24(22):3629-35
16822845
Lancet. 2005 Aug 6-12;366(9484):455-62
16084253
Oncologist. 2004;9(5):489-96
15477633
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):289-93
14623523
N Engl J Med. 2002 Feb 28;346(9):653-61
11870242
Eur Spine J. 2003 Oct;12 Suppl 2:S132-41
13680313
Ann Oncol. 2005 May;16(5):707-15
15817595
Eur J Cancer. 2005 Aug;41(12):1678-89
16098456
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
Mayo Clin Proc. 2000 Aug;75(8):821-9
10943237
Drugs Aging. 1996 May;8(5):329-37
8935395
N Engl J Med. 2003 Nov 6;349(19):1793-802
14551341
Anticancer Drugs. 1992 Oct;3(5):455-62
1450438
J Clin Oncol. 2005 Aug 1;23(22):5138-47
16009955
J Natl Cancer Inst. 2001 May 2;93(9):684-90
11333290
J Clin Oncol. 2005 Oct 20;23(30):7512-7
16234518
Breast Cancer Res. 2004;6(6):255-7
15535855
Lancet Oncol. 2008 Jan;9(1):45-53
18083636
BMJ. 1995 Oct 14;311(7011):977-80
7580638
J Clin Oncol. 1996 Jan;14(1):78-84
8558225
Clin Cancer Res. 2004 Sep 1;10(17):5717-23
15355898
J Natl Cancer Inst. 1996 Nov 6;88(21):1510-2
8901846
J Clin Oncol. 2008 Apr 20;26(12):1948-55
18332475
Ann Oncol. 2001 Nov;12(11):1527-32
11822750
Bone. 2004 Mar;34(3):384-92
15003786
J Clin Oncol. 2001 May 15;19(10):2596-606
11352951
Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):614-21
12101108
N Engl J Med. 2005 Dec 29;353(26):2747-57
16382061
J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71
16145047
Oncologist. 2004;9(2):126-36
15047917
J Clin Oncol. 2003 Jun 1;21(11):2101-9
12775735
J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42
8901851
Breast Cancer Res Treat. 1996;40(3):265-70
8883969
Ann Oncol. 2004 Feb;15(2):211-7
14760111
J Clin Oncol. 2007 Feb 10;25(5):486-92
17200148
Cancer. 2003 Nov 1;98(9):1802-10
14584060
Cancer. 2004 Sep 15;101(6):1311-22
15368322
J Clin Oncol. 2000 Apr;18(7):1570-93
10735906
J Clin Oncol. 1996 Oct;14(10):2738-46
8874335
J Clin Oncol. 2003 Nov 1;21(21):4042-57
12963702